{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:09:22Z","timestamp":1786990162434,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.htct.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T07:53:24Z","timestamp":1651564404000},"page":"402-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-2495","authenticated-orcid":false,"given":"Carla","family":"Boquimpani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-3588","authenticated-orcid":false,"given":"Fernanda Salles","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-8041","authenticated-orcid":false,"given":"Gustavo Henrique Romani","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1891-464X","authenticated-orcid":false,"given":"Ingrid Luise Soares","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1428","authenticated-orcid":false,"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-8570","authenticated-orcid":false,"given":"Jaisson Andr\u00e9 Pagnoncelli","family":"Bortolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia Borgia Barbosa","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-2552","authenticated-orcid":false,"given":"Renato","family":"Centrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-7277","authenticated-orcid":false,"given":"Vaneuza","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0001","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0002","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.htct.2022.04.002_bib0003","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","article-title":"Patients\u2019 and hematologists\u2019 concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia","volume":"144","author":"Jiang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2022.04.002_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.htct.2022.04.002_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0006","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","article-title":"The value of quality of life assessment in chronic myeloid Leukemia patients receiving tyrosine Kinase Inhibitors","volume":"2016","author":"Efficace","year":"2016","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0007","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20140014","article-title":"Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"36","author":"de Almeida","year":"2014","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"7","key":"10.1016\/j.htct.2022.04.002_bib0008","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1078155213520261","article-title":"Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia","volume":"21","author":"Anderson","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.htct.2022.04.002_bib0010","doi-asserted-by":"crossref","first-page":"A581","DOI":"10.1016\/j.jval.2016.09.1355","article-title":"Modelling the economic impact of implementing treatment-free remission (TFR) in philadelphia+ (PH+) chronic myelogenous leukemia in chronic phase (CML-CP) patients treated in first line (1l) with the tyrosine kinase inhibitors (TKI): imatinib and nilotini","volume":"19","author":"Sauvage","year":"2016","journal-title":"Value Heal"},{"key":"10.1016\/j.htct.2022.04.002_bib0011","first-page":"1","article-title":"Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon","volume":"5","author":"Elias","year":"2019","journal-title":"J Glob Oncol"},{"issue":"23","key":"10.1016\/j.htct.2022.04.002_bib0012","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood.V126.23.3293.3293","article-title":"Pharmacoeconomical analysis of chronic myelogenous leukemia treatment free remission","volume":"126","author":"Shuvaev","year":"2015","journal-title":"Blood"},{"issue":"January","key":"10.1016\/j.htct.2022.04.002_bib0013","first-page":"1","article-title":"Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients","author":"Yamazaki","year":"2020","journal-title":"Cancer Sci"},{"issue":"Supplement_1","key":"10.1016\/j.htct.2022.04.002_bib0014","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/blood-2019-127530","article-title":"Financial impact of imatinib discontinuation in brazil - a pharmoeconomic study","volume":"134","author":"Centrone","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2022.04.002_bib0015","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1182\/blood-2018-99-119200","article-title":"Impact of treatment free remission (TFR) with nilotinib in 2nd line for chronic myeloid leukemia on savings that may fund all BCR-ABL tests in the brazilian public healthcare system during and after nilotinib treatment","volume":"132","author":"Abdo","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.htct.2022.04.002_bib0016","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.htct.2022.04.002_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.htct.2022.04.002_bib0019","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.htct.2022.04.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25986","article-title":"Efficacy and safety of pioglitazone in a phase 1\/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response","volume":"95","author":"Pagnano","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.htct.2022.04.002_bib0021","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2022.04.002_bib0022","first-page":"1","article-title":"Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia","author":"Ureshino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.htct.2022.04.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106516","article-title":"MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: results of a prospective trial","volume":"101","author":"Seguro","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.htct.2022.04.002_bib0024","first-page":"1055","article-title":"Chronic myeloid leukemia","author":"Bhatia","year":"2018","journal-title":"Hematol Basic Princ Pract."},{"issue":"November","key":"10.1016\/j.htct.2022.04.002_bib0025","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.htct.2022.04.002_bib0026","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.htct.2022.04.002_bib0027","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv"},{"issue":"7\u20138","key":"10.1016\/j.htct.2022.04.002_bib0028","doi-asserted-by":"crossref","first-page":"550","DOI":"10.20344\/amp.11823","article-title":"Recommendations from a portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice","volume":"32","author":"Almeida","year":"2019","journal-title":"Acta Med Port"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"xx","key":"10.1016\/j.htct.2022.04.002_bib0030","first-page":"1","article-title":"Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian public health system (SUS): an urgent need for treatment management","author":"Boquimpani","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.htct.2022.04.002_bib0031","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.htct.2022.04.002_bib0032","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.leukres.2009.09.008","article-title":"Chronic myeloid leukemia: a disease of youth in Brazil","volume":"34","author":"de Campos","year":"2010","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.htct.2022.04.002_bib0033","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0034","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.066","article-title":"Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts","volume":"12","author":"Dragani","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"11","key":"10.1016\/j.htct.2022.04.002_bib0035","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.htct.2022.04.002_bib0036","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.htct.2022.04.002_bib0037","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.htct.2022.04.002_bib0038","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.htct.2022.04.002_bib0039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0040","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2022.04.002_bib0041","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345722","article-title":"Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a brazilian single-center cohort","volume":"130","author":"Almeida","year":"2013","journal-title":"Acta Haematol"},{"issue":"26","key":"10.1016\/j.htct.2022.04.002_bib0042","article-title":"Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan","volume":"97","author":"Tsai","year":"2018","journal-title":"Med (United States)"},{"key":"10.1016\/j.htct.2022.04.002_bib0043","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/PPA.S163393","article-title":"Chronic myeloid leukemia patients and treatment-free remission attitudes: A multicenter survey","volume":"12","author":"Lou","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.htct.2022.04.002_bib0044","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bjhh.2017.04.007","article-title":"Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia","volume":"39","author":"Vieira-Mion","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"3","key":"10.1016\/j.htct.2022.04.002_bib0045","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.htct.2022.04.002_bib0046","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0047","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.002_bib0048","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12185-019-02801-z","article-title":"Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group","volume":"111","author":"Yamaguchi","year":"2020","journal-title":"Int J Hematol"},{"issue":"55","key":"10.1016\/j.htct.2022.04.002_bib0049","first-page":"611","article-title":"NCCN guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia","volume":"17","author":"Shah","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"25","key":"10.1016\/j.htct.2022.04.002_bib0050","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.htct.2022.04.002_bib0051","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clml.2019.12.019","article-title":"Withdrawal syndrome after tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the russian prospective study RU-SKI","volume":"20","author":"Petrova","year":"2020","journal-title":"Clin Lymphoma, Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.htct.2022.04.002_bib0052","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0125-0","article-title":"Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients","volume":"8","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Blood Cancer J"},{"issue":"MAY","key":"10.1016\/j.htct.2022.04.002_bib0053","first-page":"1","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis","volume":"9","author":"kang","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.htct.2022.04.002_bib0054","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.htct.2022.04.002_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2014.991440","article-title":"Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs","volume":"31","author":"Ward","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"20","key":"10.1016\/j.htct.2022.04.002_bib0056","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2022.04.002_bib0057","article-title":"Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade","year":"2013","journal-title":"Portaria no 1.219, de 4 de novembro de 2013 - Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Leucemia Mieloide Cr\u00f4nica do Adulto [Internet]"},{"key":"10.1016\/j.htct.2022.04.002_bib0058","series-title":"Sprycel (Dasatinibe) [Bula]","first-page":"1","year":"2020"},{"key":"10.1016\/j.htct.2022.04.002_bib0059","series-title":"Tasigna (Nilotinibe) [Bula]","first-page":"1","author":"Novartis Bioci\u00eancias","year":"2020"},{"issue":"2","key":"10.1016\/j.htct.2022.04.002_bib0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","article-title":"Selecting the best frontline treatment in chronic myeloid leukemia","volume":"10","author":"Yilmaz","year":"2015","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:35:54Z","timestamp":1762868154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2531137922000505"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.04.002","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}]}}